Nerio Therapeutics Inc. has patented new tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and/or tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors reported to be useful for the treatment of cancer, type 2 diabetes, obesity and metabolic diseases.

Gasherbrum Bio Inc. patent details heterocyclic glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of type 2 diabetes, among others.

Oncopia Therapeutics Inc. (dba Proteovant Therapeutics Inc.) and the University of Michigan have jointly patented molecular glue degraders targeting cereblon (CRBN) and acting as zinc finger protein Helios (IKZF2) degradation inducers.

Eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) degradation inducers have been reported in a Bristol Myers Squibb Co. patent as potentially useful for the treatment of cancer.

Atrin Pharmaceuticals Inc. has disclosed ATR kinase inhibitors potentially useful for the treatment of cancer.

Zydus Lifesciences Ltd. has patented compounds reported to be useful for the treatment of osteoarthritis.

Prism Biolab Co. Ltd. has identified new 7-membered ring-fused compounds acting as Notch signaling inhibitors and reported to be potentially useful for the treatment of neuronal injury and neurodegenerative diseases.

Hyperway Pharmaceutical Co. Ltd. and Shenzhen Hyperway Pharmaceuticals Co. Ltd. have disclosed new GTPase KRAS (G12D mutant) inhibitors.

Bioversys AG has prepared rifabutin analogues reported to be useful for the treatment of bacterial infections.

Substituted fluorinated N-propyl-pyrrolidine and n-propyl-azetidine compounds acting as estrogen receptor (ER) antagonists and selective estrogen receptor degradation (SERD) inducers have been reported in a Sanofi SA patent.